Adenocarcinoma of the Pancreas Withdrawn Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Adenocarcinoma, Pancreatic / Adenocarcinoma of Pancreas / Pancreas Adenocarcinoma / Adenocarcinoma, Pancreas / Pancreatic Adenocarcinoma / Pancreas, Adenocarcinoma / Adenocarcinoma Pancreas

IndicationStatusPhase
DBCOND0029532 (Adenocarcinoma of the Pancreas)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04045730The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.Treatment
NCT03432676Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic CancerTreatment